MECP2 and breast carcinoma: Given abnormal DNA methylation in breast cancers (10, 12, 62, 63) and MeCP2 amplification in cancers (41), we wanted to identify new MeCP2 target genes and map novel sites of MeCP2 post-translational acetylation in breast cancer cells.